Immunocore develops innovative biological therapeutics that exploit the power of the body’s own immune system to find and kill diseased cells. The foundation partnered with the company to expand its focus into infectious disease.
Program Areas: Discovery & Translational Science
The foundation invested in CureVac to accelerate vaccine technology development, getting life-saving and low-cost vaccines to people who need them most.
Arsanis is focused on discovery and development of novel monoclonal antibodies (“mAbs”) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis which leads to approximately 345,000 annual deaths globally.
Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation partnered with the team to support development of preclinical drug candidates.
Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation’s investment is supporting the development of Achaogen’s monoclonal antibody (“mAb”) discovery platform.
Press Release: Arsanis Announces Closing of Initial Public Offering
November 20, 2017 WALTHAM, Mass. and VIENNA–(BUSINESS WIRE Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its Read More
Endpoints: Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study
By John Carrol October 5, 2017 At the time Visterra made a bid early this year to go public, the timing was off. The boom of 2014 was long gone and the current bumper crop of IPOs had yet to Read More
Press Release: Archaogen receives investment from the Bill & Melinda Gates Foundation to develop antibodies against gram-negative bacteria
Achaogen May 5, 2017 Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced that it has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to partner in Read More
Xconomy: Gates Foundation Leads $45.5M Round for Gerngross’s Biotech Arsanis
By David Holley April 26, 2017 Arsanis, a Waltham, MA-based biotech co-founded by scientist and entrepreneur Tillman Gerngross to develop treatments for bacterial and viral infections, has raised a $45.5 million investment led by the Bill & Melinda Gates Foundation to finance a mid-stage Read More
Press Release: Arsanis Completes $45.5 Million Series D Financing
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced the closing of a $45.5 million Series D financing led by the Bill & Melinda Gates Foundation. Several Read More